ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "ARIAD Pharmaceuticals, Inc." (ARIA) Report Updated: Nov 24, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"ARIAD Pharmaceuticals, Inc." (ARIA)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: ENTA, MDXG, CMRX, RNA

Stock Analysis

Rating: Monthly View

A
B
C
D
F
November December January February March April May June July August September October

Rating: Weekly View

This Week: B down no change
Last Week: B same no change
Two Weeks Ago: B up no change
service keys

"ARIAD Pharmaceuticals, Inc."© quotemedia

Company Profile

ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. Its product pipeline includes Ponatinib, an investigational pan BCR-ABL inhibitor, which is being studied in Phase I and II clinical trials in patients with hematologic cancers, including chronic myeloid leukemia and Philadelphia positive acute lymphoblastic leukemia; AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a Phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; and Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers. The company also focuses on a drug discovery program centered on small-molecule therapies that are molecularly targeted to cell-signaling pathways implicated in cancer. ARIAD Pharmaceuticals, Inc. has a collaboration agreement with Merck for the joint global development, manufacture, and commercialization of ridaforolimus for use in cancer; and license agreements with Medinol and ICON to develop and commercialize ridaforolimus-eluting stents and other medical devices to prevent restenosis or reblockage of injured vessels following interventions in which stents are used in conjunction with balloon angioplasty. The company was founded in 1991 and is headquartered in Cambridge, Massachusetts.

Recent News: "ARIAD Pharmaceuticals, Inc."